imgboxbg

Press Release

Category brief summary: 公司新闻
NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio
NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio
September 10th,2019, IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, announced today that the Company has received 
See more information
September 10th,2019, IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, announced today that the Company has received 
Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings
Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings
IASO Biotherapeutics (IASO Bio),one of the top biotechnology innovators, announced that potential best-in-class therapy back-to-back at two of the most prestigious clinical meetings in the worlds of hematology and oncology
See more information
IASO Biotherapeutics (IASO Bio),one of the top biotechnology innovators, announced that potential best-in-class therapy back-to-back at two of the most prestigious clinical meetings in the worlds of hematology and oncology
Previous
1

驯鹿医疗